COVID-19 May Triple the Risk of Death During NSCLC Treatment
Patients with non-small cell lung cancer may have a 3-fold higher risk of death if they develop COVID-19, a study suggests.
Patients with non-small cell lung cancer may have a 3-fold higher risk of death if they develop COVID-19, a study suggests.
Women are underrepresented in clinical trials of NSCLC treatment, a meta-analysis suggests.
A study of patients with advanced lung-limited colorectal cancer has revealed factors associated with undergoing pulmonary metastasectomy.